Preventive Alzheimer's trial data due within weeks, Lilly says

Eli Lilly executives on Thursday said they expect a closely watched preventive study of the pharma's Alzheimer's disease drug solanezumab to yield results this quarter. The university-sponsored trial, called DIAN-TU, is testing patients with genetic mutations that cause early and severe cognitive declines.